Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Erythema: early-phase trial registry

A small indexed set (10 trials) with no open enrollment listed right now.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · none currently recruiting · #1,724 of 28,707 conditions by registered trial count

Erythema: 10 US clinical trials tracked, none currently recruiting.

Erythema is the subject of 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Church & Dwight Company, running 3 of these trials.

Enrollment posture brief

Registry condition erythema

OPEN 0 | RECR 0% | LATE 1 | EARLY 4 | RANK #1724 | SPON 3

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Erythema (this)0%
Open-enrollment share among volume-matched conditions near Erythema

Erythema has no open enrollment in this registry pull (10 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Erythema on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Erythema is recruiting below its size-band peers.

    0 of 10 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Erythema research.

    Church & Dwight Company accounts for 3 of 10 trials (30%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Erythema trials plan to enrol fewer than 100 people.

    Median target enrolment is 64 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.

  4. Erythema research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23Phase 31

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2 71 participants

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

M.D. Anderson Cancer Center

NCT02411656

ACTIVE NOT RECRUITING Phase 2 42 participants

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

M.D. Anderson Cancer Center

NCT02876107

COMPLETED Phase 2 357 participants

AGN-199201 for the Treatment of Erythema With Rosacea

Allergan

NCT01735201

COMPLETED NA 222 participants

Human Repeat Insult Patch Test to Evaluate Personal Lubricants

Church & Dwight Company

NCT02737631

COMPLETED Phase 3 70 participants

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

Galderma R&D

NCT01659853

COMPLETED Phase 1 64 participants

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

Allergan

NCT01579084

COMPLETED NA 60 participants

A Comparison of INSORB Staples With Metal Staples in Total Hip Replacement

Orthopaedic Research Foundation

NCT00940446

COMPLETED NA 35 participants

Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin

University of California, Davis

NCT03477825

COMPLETED NA 32 participants

A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects

Church & Dwight Company

NCT02737852

COMPLETED NA 30 participants

A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects

Church & Dwight Company

NCT02320214

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Erythema records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AGN-199201 Vehicle Drug
2 trials
Laboratory Biomarker Analysis Other
2 trials
AGN-199201 Dose C Drug
1 trials
AGN-199201 Dose B Drug
1 trials
AGN-199201 Dose A Drug
1 trials
AGN-199201 Formulation C Drug
1 trials
AGN-199201 Formulation B Drug
1 trials
AGN-199201 Formulation A Drug
1 trials

US sites by state

Facility locations filed on Erythema trials. A trial with sites in several states counts in each.

Texas 5 trials
New Jersey 3 trials
Indiana 2 trials
Virginia 1 trials
Kentucky 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Erythema page

10 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Erythema trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Church & Dwight Company sponsors the most Erythema trials on record, review their full trial history before evaluating a specific study. See Church & Dwight Company's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Erythema condition card totals 10 registered trials; most-linked intervention AGN-199201 Vehicle; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.